Raptiva Heading For Suspension?

The US FDA has announced a public health advisory concerning three confirmed cases and possibly a fourth of progressive multifocal leukoencephalopathy (PML) in patients using Genentech's Raptiva (efalizumab), which is approved to treat psoriasis. Three of the patients have died. In October 2008, Raptiva's product labelling was changed to include a black box warning highlighting the risks of life-threatening infections including PML.

To read the full article, please choose one of the following options: